Interleukin-17A (IL-17A) is generally considered as one of the pathogenic factors involved in multiple sclerosis (MS). Indirect evidence for this is that IL-17A-producing T helper 17 (Th17) cells preferentially accumulate in lesions of MS and experimental autoimmune encephalomyelitis (EAE). However, a direct involvement of IL-17A in MS pathogenesis is still an open question. In this study, we overexpressed IL-17A in the brains of mice (IL-17A-in-Brain mice) via recombinant adeno-associated virus serotype 5 (rAAV5)-mediated gene delivery. In spite of high levels of IL-17A expression in the brain and blood, IL-17A-in-Brain mice exhibit no inflammatory responses and no abnormalities in motor coordination and spatial orientation. Unexpectedly, IL-17A-in-Brain mice show decreases in body weight and adipose tissue mass and an improvement in glucose tolerance and insulin sensitivity. IL-17A enhances glucose uptake in PC12 cells by activation of AKT. Our results provide direct evidence for the first time that IL-17A overexpression in the central nervous system does not cause physical and learning disabilities and neuroinflammation and suggest that IL-17A may regulate glucose metabolism through the AKT signaling pathway.
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Introduction
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) causing severe physical and cognitive problems (Rocca et al., 2015; Sumowski and Leavitt, 2013) . The mounting evidence suggests that T helper 1 (Th1) and T helper 17 (Th17) cells are the main immunological players, resulting in experimental autoimmune encephalomyelitis (EAE) and MS (Babaloo et al., 2015; Hofstetter et al., 2009; Legroux and Arbour, 2015; Liu et al., 2014; Platten et al., 2009; Tzartos et al., 2008; Wang et al., 2009 ). Th1 cells, however, migrate across the blood-brain barrier into the CNS less efficiently than Th17 cells (Kebir et al., 2007; Marwaha et al., 2012) . Emerging studies show predominant accumulation of Th17 cells in EAE and MS lesions, indirectly indicating that Th17 cells are a key regulator of MS and EAE pathogenesis. Th17 cells produce IL-17A, IL-17F, IL-21 and IL-22 (Kreymborg et al., 2007; Murugaiyan et al., 2015; Nurieva et al., 2007) . Among them, IL-17A, signature cytokine of Th17 cells, is often increased in patients with the autoimmune disease (Hemdan et al., 2010; Lock et al., 2002; Matusevicius et al., 1999; Zepp et al., 2011) .
IL-17A, cloned in 1993 by Rouvier et al. (Rouvier et al., 1993) , is one of the IL-17 family members which also include IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. Among the IL-17 family, IL-17A is most investigated in many inflammatory conditions such as autoimmune diseases (Koenders et al., 2005; Kuchroo et al., 2012; Lubberts et al., 2005) and metabolic disorders (Ahmed and Gaffen, 2010, 2013; Zuniga et al., 2010) . It is widely accepted that IL-17A promotes autoimmunity, especially in the context of rheumatoid arthritis (RA), psoriasis, MS and a rodent model of MS, EAE (Kang et al., 2010 (Kang et al., , 2013 Kulcsar et al., 2014; Lock et al., 2002; Lubberts, 2008; Qian et al., 2007) . Indeed, anti-IL-17RA antibodies in clinical trials have shown efficacy in psoriasis, RA and MS (Hueber et al., 2010; Luchtman et al., 2014; Mease et al., 2014; Yang et al., 2014) . Furthermore, certain investigators have shown that EAE is substantially reduced in IL-17a À/À or IL-17ar À/À mice
